Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Gabapentin Market Growth & Trends

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising usage of gabapentin for neuropathic pain and the increasing incidence of associated diseases such as epilepsy globally. The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.

The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.

Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.

North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.

Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.

Gabapentin Market Report Highlights

• Capsules dominated the market and accounted for a share of 56.1% in 2024. This is attributed to their ease of administration, which makes them ideal for patients, including children and the elderly.
• Generic gabapentin led the market with a revenue share of 90.1% in 2024. Generics provide a cost-effective alternative to branded medications, expanding accessibility for a wider patient demographic.
• Applications in epilepsy held the largest market share of 49.9% in 2024, owing to its proven efficacy as an anticonvulsant essential for seizure management in individuals with epilepsy.
• Hospital pharmacies dominated the market and accounted for a share of 47.6% in 2024, serving as key healthcare facilities for treating chronic conditions such as epilepsy and neuropathic pain.
• North America gabapentin market dominated the global market with a revenue share of 33.7% in 2024.

Please note The report will be delivered in 2-3 business days upon order notification.